Literature DB >> 28801709

DEX implant intravitreal injection, sustained intraocular hypertension, and steroid-induced glaucoma in patients with no risk factors.

Amina Rezkallah1, Laurent Kodjikian2, Ariane Malclès2, Corinne Dot3,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28801709     DOI： 10.1007/s00417-017-3773-z

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN： 0721-832X            Impact factor:   3.117


× No keyword cloud information.
  5 in total

1.  EFFECT OF CORTICOSTEROIDS ON INTRAOCULAR PRESSURE AND FLUID DYNAMICS. II. THE EFFECT OF DEXAMETHASONE IN THE GLAUCOMATOUS EYE.

Authors:  M F ARMALY
Journal:  Arch Ophthalmol       Date:  1963-10

2.  Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema.

Authors:  David S Boyer; Young Hee Yoon; Rubens Belfort; Francesco Bandello; Raj K Maturi; Albert J Augustin; Xiao-Yan Li; Harry Cui; Yehia Hashad; Scott M Whitcup
Journal:  Ophthalmology       Date:  2014-06-04       Impact factor: 12.079

3.  SAFETY OF INTRAVITREAL DEXAMETHASONE IMPLANT (OZURDEX): The SAFODEX study. Incidence and Risk Factors of Ocular Hypertension.

Authors:  Ariane Malclès; Corinne Dot; Nicolas Voirin; Anne-Laure Vié; Émilie Agard; David Bellocq; Philippe Denis; Laurent Kodjikian
Journal:  Retina       Date:  2017-07       Impact factor: 4.256

Review 4.  [Ocular hypertension after intravitreal steroid injections: Clinical update as of 2015].

Authors:  C Dot; H El Chehab; A Russo; E Agard
Journal:  J Fr Ophtalmol       Date:  2015-06-19       Impact factor: 0.818

5.  TOLERANCE OF INTRAVITREAL DEXAMETHASONE IMPLANTS IN PATIENTS WITH OCULAR HYPERTENSION OR OPEN-ANGLE GLAUCOMA.

Authors:  Anne-Laure Vié; Laurent Kodjikian; Ariane Malclès; Emilie Agard; Nicolas Voirin; Hussam El Chehab; Anh-Minh Nguyen; Corinne Dot
Journal:  Retina       Date:  2017-01       Impact factor: 4.256
  5 in total
  5 in total

1.  Sodium 4-Phenylbutyrate Reduces Ocular Hypertension by Degrading Extracellular Matrix Deposition via Activation of MMP9.

Authors:  Prabhavathi Maddineni; Ramesh B Kasetti; Bindu Kodati; Sam Yacoub; Gulab S Zode
Journal:  Int J Mol Sci       Date:  2021-09-18       Impact factor: 6.208

2.  Impact of systemic steroids combined with immunosuppressive treatment on glaucomatous features in patients with systemic lupus erythematosus.

Authors:  Marta P Wiącek; Danuta Bobrowska-Snarska; Marek Brzosko; Wojciech Lubiński; Monika Modrzejewska
Journal:  Int J Ophthalmol       Date:  2022-01-18       Impact factor: 1.779

3.  Post-marketing surveillance study of the safety of dexamethasone intravitreal implant in patients with retinal vein occlusion or noninfectious posterior segment uveitis.

Authors:  Adnan Tufail; Sue Lightman; Ahmed Kamal; Uwe Pleyer; Nuria María Gajate Paniagua; Corrine Dot; Xiao-Yan Li; Jenny Jiao; Jean Lou; Yehia Hashad
Journal:  Clin Ophthalmol       Date:  2018-12-06

4.  Sustained Intraocular Pressure Rise after the Treat and Extend Regimen at 3 Years: Aflibercept versus Ranibizumab.

Authors:  Alper Bilgic; Laurent Kodjikian; Jay Chhablani; Anand Sudhalkar; Megha Trivedi; Viraj Vasavada; Vaishali Vasavada; Shail Vasavada; Samaresh Srivastava; Deepak Bhojwani; Aditya Sudhalkar
Journal:  J Ophthalmol       Date:  2020-01-20       Impact factor: 1.909

Review 5.  Current intravitreal therapy and ocular hypertension: A review.

Authors:  Aditya Sudhalkar; Alper Bilgic; Shail Vasavada; Laurent Kodjikian; Thibaud Mathis; Fransesc March de Ribot; Thanos Papakostas; Viraj Vasavada; Vaishali Vasavada; Samaresh Srivastava; Deepak Bhojwani; Pooja Ghia; Anand Sudhalkar
Journal:  Indian J Ophthalmol       Date:  2021-02       Impact factor: 1.848
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.